Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 9/20 | 0.55 |
| ▸ | ROCK1 | Q13464 | 6/20 | 0.52 |
| ▸ | FLT1 | P17948 | 2/20 | 0.47 |
| ▸ | EGFR | P00533 | 2/20 | 0.47 |
| ▸ | PAK4 | O96013 | 5/20 | 0.46 |
| ▸ | ULK1 | O75385 | 1/20 | 0.46 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.46 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | FYN | P06241 | 1/20 | 0.44 |
| ▸ | CSF1R | P07333 | 1/20 | 0.44 |
| ▸ | RET | P07949 | 1/20 | 0.44 |
| ▸ | IGF1R | P08069 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13220345 | 0.90 | ROCK2 (0.52) | ROCK2ROCK1FLT1EGFRPAK4 | |
| SCHEMBL13220503 | 0.89 | ROCK2 (0.51) | ROCK2ROCK1FLT1EGFRPAK4 | |
| SCHEMBL13220333 | 0.89 | ROCK2 (0.51) | ROCK2ROCK1FLT1EGFRPAK4 | |
| SCHEMBL13220520 | 0.88 | EGFR (0.53) | ROCK2ROCK1FLT1EGFRPAK4 | |
| SCHEMBL13220410 | 0.88 | ROCK2 (0.52) | ROCK2ROCK1FLT1EGFRPAK4 | |
| SCHEMBL13547630 | 0.88 | ROCK2 (0.54) | ROCK2ROCK1FLT1EGFRPAK4 | |
| SCHEMBL13220473 | 0.87 | ROCK2 (0.50) | ROCK2ROCK1FLT1EGFRPAK4 | |
| SCHEMBL13220435 | 0.87 | CDC7 (0.58) | ROCK2ROCK1FLT1EGFRPAK4 | |
| SCHEMBL13220422 | 0.87 | ROCK2 (0.55) | ROCK2ROCK1FLT1EGFRPAK4 | |
| SCHEMBL13220452 | 0.87 | ROCK2 (0.55) | ROCK2ROCK1FLT1EGFRPAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216789-A1 | RHO-KINASE INHIBITORS | NAGARATHNAM DHANAPALAN | 2010-08-26 | — | — | US | disclosed |
| US-20100216789-A1 | RHO-KINASE INHIBITORS | NAGARATHNAM DHANAPALAN | 2010-08-26 | — | — | US | disclosed |
| US-20100216789-A1 | RHO-KINASE INHIBITORS | NAGARATHNAM DHANAPALAN | 2010-08-26 | — | — | US | disclosed |
| US-7648986-B2 | Substituted thieno[3,2-D]pyrimidines as Rho kinase inhibitors | BAYER HEALTHCARE LLC (US) | 2010-01-19 | — | — | US | disclosed |
| US-7648986-B2 | Substituted thieno[3,2-D]pyrimidines as Rho kinase inhibitors | BAYER HEALTHCARE LLC (US) | 2010-01-19 | — | — | US | disclosed |
| US-7648986-B2 | Substituted thieno[3,2-D]pyrimidines as Rho kinase inhibitors | BAYER HEALTHCARE LLC (US) | 2010-01-19 | — | — | US | disclosed |
| EP-1465900-B1 | RHO-KINASE INHIBITORS | BAYER HEALTHCARE AG (DE) | 2008-05-14 | — | — | EP | disclosed |
| EP-1465900-B1 | RHO-KINASE INHIBITORS | BAYER HEALTHCARE AG (DE) | 2008-05-14 | — | — | EP | disclosed |
| US-20070238741-A1 | Hypertension, atherosclerosis, restenosis, cerebral ischemia, cerebral vasospasm, or erectile dysfunction; 2-(5-chloro-2-thienyl)-N-(1H-indazol-5-yl)thieno[3,2-d]pyrimidin-4-amine | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-10-11 | — | — | US | disclosed |
| US-20070238741-A1 | Hypertension, atherosclerosis, restenosis, cerebral ischemia, cerebral vasospasm, or erectile dysfunction; 2-(5-chloro-2-thienyl)-N-(1H-indazol-5-yl)thieno[3,2-d]pyrimidin-4-amine | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-10-11 | — | — | US | disclosed |
| US-20070238741-A1 | Hypertension, atherosclerosis, restenosis, cerebral ischemia, cerebral vasospasm, or erectile dysfunction; 2-(5-chloro-2-thienyl)-N-(1H-indazol-5-yl)thieno[3,2-d]pyrimidin-4-amine | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-10-11 | — | — | US | disclosed |
| US-20040014755-A1 | Rho-kinase inhibitors | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014755-A1 | Rho-kinase inhibitors | CIT, ROCK1, ROCK2 | ROCK2 3/4885ROCK1 2/4885FLT1 699/4885 |
| US-20100216789-A1 | RHO-KINASE INHIBITORS | CIT, ROCK1, ROCK2 | ROCK2 3/4885ROCK1 2/4885FLT1 699/4885 |
| US-20070238741-A1 | Hypertension, atherosclerosis, restenosis, cerebral ischemia, cerebral vasospasm, or erectile dysfunction; 2-(5-chloro-2-thienyl)-N-(1H-indazol-5-yl)thieno[3,2-d]pyrimidin-4-amine | CIT, PTGIS, PTGIR | ROCK2 8/4885ROCK1 7/4885FLT1 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.